Work

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K

Year: 2022

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(22)00824-3

Authors: K. Kalinsky, W. Zihan, C. McCourt, E.P. Mitchell, J.J. Wright, L.A. Doyle, R.J. Gray, V. Wang, L.M. McShane, L.V. Rubinstein, D. Patton, P.M. Williams, S.R. Hamilton, B.A. Conley, C.A. Arteaga, L.N. Harris, P.J. O’Dwyer, A.P. Chen, K.T. Flaherty

Institutions: Emory University, Winship Cancer Institute, Dana-Farber Cancer Institute, Washington University in St. Louis, Thomas Jefferson University Hospital, National Cancer Institute, Frederick National Laboratory for Cancer Research, City Of Hope National Medical Center, The University of Texas Southwestern Medical Center, University of Pennsylvania, Massachusetts General Hospital

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4307908375

FWCI: 0.483

Cites:

Cited by: 7

Related to: 10